Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...

Evorpacept improved tumor response in patients with HER2-positive gastric/GEJ cancer, becoming the first ... TRP to an assumed RP control ORR of 30% Secondary endpoints of PFS and OS were immature ...

We anticipate achieving several additional clinical milestones in the near-term that could advance evorpacept towards being a best-in-class, combinable therapeutic across a wide range of cancer types ...

After a comprehensive two-year follow-up, researchers at the UCLA Health Jonsson Comprehensive Cancer Center found that ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...

According to study findings published in Cancer, “Our findings highlight the need for further ... The primary goal of this trial was the objective response rate. Secondary goals included ...

Nov. 11, 2024 — A team of scientists has used a novel approach to identify protein degraders that target Pin1, a protein involved in pancreatic cancer ... DNA Packaging Directly Affects How Fast ...

The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen alongside bortezomib, lenalidomide, and dexamethasone (VRd), for ...

small secondary cancers might be clinically irrelevant if the index lesion is treated The future success of focal therapy will depend on adequate prostate sampling at biopsy, along with accurate ...

Sarclisa has been available for this indication under the Cancer Drugs Fund (CDF) for patients who have had at least three prior lines of treatment since 2020 and, according to Sanofi, has become ...

GenesisCare, the UK’s leading private cancer care provider, has launched a thought-provoking photography exhibition to raise awareness of where secondary breast cancer might occur in the body at its ...